Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
With
TARIS Biomedical, Inc.
The study is conducted in 2 parts - a randomized, blinded part in which patients are randomly assigned to one of 3 possible arms (LiRIS® - contains lidocaine), LiRIS Placebo (LiRIS with inactive substance) or Sham(Insertion procedure only with neither LiRIS nor LiRIS Placebo), followed by an open extension part in which all patients are assigned to receive LiRIS® (with lidocaine). In part 1 of the study, treatment is managed in a double-blind manner for LiRIS® and LiRIS Placebo arms; and in a single-blind manner for the Sham arm (e.g.,the study doctor will know the treatment assignment for patients assigned to Sham).
All patients who complete part 1 of the study have the option to enter the extension.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women age 18 and over
Diagnosed with Interstitial Cystitis as defined by protocol
Able and willing to complete questionnaires and diary
Able to comply with visit schedule including Day 14 Removal visit
Completion of blinded study prior to enrolling in unblinded part of study
You may not be if
Pregnant or lactating women
Bladder or urethra anatomical feature that would prevent the safe indwelling or insertion of the investigational product
History or presence of any condition that would make it difficult to evaluate symptoms
Did not complete blinded study (unblinded part of study only)